Iscalimab, an anti-CD40 monoclonal antibody, showed preliminary efficacy for the treatment of primary Sjögren syndrome (pSS) in a phase II placebo-controlled trial (n = 44). Of the two administration routes tested (intravenous and subcutaneous), only intravenous iscalimab resulted in a significant reduction in the EULAR Sjögren’s syndrome disease activity index (ESSDAI) score after 12 weeks of treatment compared with placebo (95% CI 0.96–9.46; one-sided P = 0.0090). Only two severe adverse events were reported across all groups, neither of which was related to iscalimab.
References
Original article
Fisher, B. A. et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(19)30135-3 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clarke, J. CD40 blockade shows promise in pSS trial. Nat Rev Rheumatol 16, 126 (2020). https://doi.org/10.1038/s41584-020-0380-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0380-x
